Background. Development of pre-clinical models of long-lasting inflammation is needed for the study of inflammatory diseases. Osteoarthritis (OA), the most common inflammatory joint pathology, is characterized by an abundance of M1-like macrophages producing several pro-inflammatory cytokines and proteolytic enzymes damaging the local tissues. Here we developed a novel in vitro model of long-lasting inflammation using primary human monocyte-derived macrophages continuously cultured for 15 days.
Results. We first screened synovial fluids from 11 OA patients using multiplex Ella® and we found measurable levels of IL-6, CCL2, CCL5, CXCL8, CXCL10, TNFa, IL-1b, using them as read-outs of the following experiments. We then found an increased survival of macrophages differentiated with both M-CSF and GM-CSF (M-/GM-Mf) compared either with macrophages differentiated with M-CSF alone (M-Mf) or macrophages differentiated with GM-CSF alone (GM-Mf) and, consequently, decided to use them to set up the in vitro model of long-lasting inflammation. Consistently with the increased survival, the repeated stimulation of M-/GM-Mfs either with lipopolysaccharide + interferon-g (LPS+IFN-g) or Pam3CysSerLys4 (Pam3CSK4) led to the sustained production of IL-6, CCL2 and CXCL8 over time. Finally, to investigate the usefulness of our model for OA research, we repeatedly exposed stimulated macrophages to dexamethasone (DEX) and/or celecoxib (CEL), two anti-inflammatory drugs commonly used for OA therapy. We found an excellent anti-inflammatory activity but significant toxicity of DEX for concentrations over 10 nM, while CEL was not toxic and efficiently inhibited PGE2 secretion. Of interest, the inflammatory profile of macrophages differentiated with M-CSF or GM-CSF and activated with the two pro-inflammatory stimuli (LPS+IFN-g vs Pam3CSK4) was not identical, overall showing production of more inflammatory mediators with GM-CSF-macrophages stimulated with Pam3CSK4.
Conclusions. We introduce here a novel easy-to-use in vitro culture model of long-lasting inflammation using primary human macrophages, that could be useful for the screening of new compounds and drug delivery systems, to improve the therapy of inflammatory disorders.